Sangamo Therapeutics, Inc.(SGMO)

$0.07—Stale · unknown old

Ask SA Chart

Sangamo Therapeutics, Inc.(SGMO)

OTCMARKET • Last print unknown ago

$0.07—Stale · unknown old

Ask SA Chart Studio

SGMO(SGMO)

SGMO

Overview Fair Value Stream Notebook Intel Chart History Fundamentals TTM Earnings Analysts News Financials Insiders Institl.DCF Peers

FY2029 EPS Estimate

$0.06

FY2029E EPS$0.06

FY2030E EPS$0.13

Analyst Sentiment

Wall St. Consensus

Hold

13 analysts·Moderate coverage

Score

6 Buy (46%)6 Hold (46%)1 Sell (8%)

Rating Breakdown

Strong Buy

00%

Buy

646%

Hold

646%

Sell

18%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear

$2.00

+2602.7%

Consensus

$4.00

+5305.4%

Bull

$19.00

+25575.7%

12-Month Target Range13 analysts

$2.00$4.00$19.00

Current $0.07Consensus

Current Price

$0.07

Upside to Consensus

$3.93

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)

FY2027

Rev+615.15%

EPS—

FY2028

Rev+99.01%

EPS—

FY2029

Rev+48.62%

EPS—

Raw consensus estimates (low / average / high) from covering analysts.

Annual

Metric	FY2026E	FY2027E	FY2028E	FY2029E	FY2030E
Revenue Avg	$10M	$71M	$141M	$209M	$269M
Low	$10M	$71M	$141M	$209M	$269M
High	$10M	$71M	$141M	$209M	$269M
EBITDA Avg	$-78M	$-22M	$3M	$32M	$60M
Low	$-78M	$-22M	$3M	$32M	$60M
High	$-78M	$-22M	$3M	$32M	$60M
EBIT Avg	$-84M	$-28M	$-6M	$21M	$46M
Low	$-84M	$-28M	$-6M	$21M	$46M
High	$-84M	$-28M	$-6M	$21M	$46M
Net Income Avg	$-84M	$-28M	$-6M	$17M	$36M
Low	$-84M	$-28M	$-6M	$17M	$36M
High	$-84M	$-28M	$-6M	$17M	$36M
EPS Avg	$-0.30	$-0.10	$-0.02	$0.06	$0.13
Low	$-0.30	$-0.10	$-0.02	$0.06	$0.13
High	$-0.30	$-0.10	$-0.02	$0.06	$0.13
Analysts (Rev / EPS)	1 / 1	1 / 1	1 / 1	1 / 1	1 / 1

Quarterly

Metric	Q3 2026	Q4 2026	Q1 2027	Q2 2027	Q3 2027	Q4 2027
Revenue Avg	$500,000	$2M	$11M	$14M	$18M	$28M
Low	$500,000	$2M	$11M	$14M	$18M	$28M
High	$500,000	$2M	$11M	$14M	$18M	$28M
EBITDA Avg	$-30M	$-26M	$-19M	$-15M	$-15M	$-7M
Low	$-30M	$-26M	$-19M	$-15M	$-15M	$-7M
High	$-30M	$-26M	$-19M	$-15M	$-15M	$-7M
EBIT Avg	$-31M	$-27M	$-19M	$-16M	$-16M	$-8M
Low	$-31M	$-27M	$-19M	$-16M	$-16M	$-8M
High	$-31M	$-27M	$-19M	$-16M	$-16M	$-8M
Net Income Avg	$-31M	$-27M	$-19M	$-16M	$-16M	$-8M
Low	$-31M	$-27M	$-19M	$-16M	$-16M	$-8M
High	$-31M	$-27M	$-19M	$-16M	$-16M	$-8M
EPS Avg	$-0.08	$-0.07	$-0.05	$-0.04	$-0.04	$-0.02
Low	$-0.08	$-0.07	$-0.05	$-0.04	$-0.04	$-0.02
High	$-0.08	$-0.07	$-0.05	$-0.04	$-0.04	$-0.02
Analysts (Rev / EPS)	2 / 1	1 / 1	1 / 1	1 / 1	1 / 1	1 / 1

Earnings Surprises

Recent Analyst Actions

Dec 31, 2024Jefferies

Sangamo price target lowered to $3 from $7 at Jefferies

Target:$3.00

+194.1%from $1.02

Dec 31, 2024Wells Fargo

Sangamo price target lowered to $2 from $3 at Wells Fargo

Target:$2.00

+96.1%from $1.02

Jun 13, 2022Wedbush

Sangamo assumed with a Neutral at Wedbush

Target:$5.00

+33.0%from $3.76

Apr 5, 2022Truist Financial

Sangamo BioSciences (SGMO) Stock: Why The Price Increased

Target:$19.00

+208.9%from $6.15

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance